Johnson & Johnson (JNJ)vsMettler-Toledo International Inc (MTD)
JNJ
Johnson & Johnson
$275.19
+1.53%
HEALTHCARE · Cap: $615.87B
MTD
Mettler-Toledo International Inc
$1,698.47
+0.78%
HEALTHCARE · Cap: $32.84B
Smart Verdict
WallStSmart Research — data-driven comparison
Johnson & Johnson generates 2303% more annual revenue ($99.33B vs $4.13B). MTD leads profitability with a 21.9% profit margin vs 16.2%. MTD appears more attractively valued with a PEG of 2.77. MTD earns a higher WallStSmart Score of 64/100 (C+).
JNJ
Buy57
out of 100
Grade: C
MTD
Buy64
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-83.0%
Fair Value
$144.12
Current Price
$275.19
$131.07 premium
Intrinsic value data unavailable for MTD.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Strong operational efficiency at 25.1%
Generating 6.4B in free cash flow
Strong operational efficiency at 31.2%
Safe zone — low bankruptcy risk
Every $100 of equity generates 30 in profit
Keeps 22 of every $100 in revenue as profit
Areas to Watch
Premium valuation, high expectations priced in
Weak financial health signals
Expensive relative to growth rate
Earnings declined 96.0%
Premium valuation, high expectations priced in
4.5% revenue growth
Expensive relative to growth rate
Trading at 2653.9x book value
Comparative Analysis Report
WallStSmart ResearchBull Case : JNJ
The strongest argument for JNJ centers on Market Cap, Operating Margin, Free Cash Flow. Profitability is solid with margins at 16.2% and operating margin at 25.1%.
Bull Case : MTD
The strongest argument for MTD centers on Operating Margin, Altman Z-Score, Return on Equity. Profitability is solid with margins at 21.9% and operating margin at 31.2%.
Bear Case : JNJ
The primary concerns for JNJ are P/E Ratio, Piotroski F-Score, PEG Ratio.
Bear Case : MTD
The primary concerns for MTD are P/E Ratio, Revenue Growth, PEG Ratio. Debt-to-equity of 164.70 is elevated, increasing financial risk.
Key Dynamics to Monitor
JNJ profiles as a mature stock while MTD is a value play — different risk/reward profiles.
MTD carries more volatility with a beta of 1.19 — expect wider price swings.
JNJ is growing revenue faster at 5.9% — sustainability is the question.
JNJ generates stronger free cash flow (6.4B), providing more financial flexibility.
Bottom Line
MTD scores higher overall (64/100 vs 57/100), backed by strong 21.9% margins. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Johnson & Johnson
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Johnson & Johnson (J&J) is an American multinational corporation founded in 1886 that develops medical devices, pharmaceuticals, and consumer packaged goods. Its common stock is a component of the Dow Jones Industrial Average and the company is ranked No. 36 on the 2021 Fortune 500 list of the largest United States corporations by total revenue. Johnson & Johnson is one of the world's most valuable companies, and is one of only two U.S.-based companies that has a prime credit rating of AAA, higher than that of the United States government.
Visit Website →Mettler-Toledo International Inc
HEALTHCARE · DIAGNOSTICS & RESEARCH · USA
Mettler Toledo (NYSE: MTD) is a multinational manufacturer of scales and analytical instruments. It is the largest provider of weighing instruments for use in laboratory, industrial, and food retailing applications. The company also provides various analytical instruments, process analytics instruments, and end-of-line inspection systems.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?